Theravance Biopharma TBPH Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $114.54M+296% | $105.9M+288% | $29.34M+159% | $13.03M+129% | -$58.33M-30.3% | ||
| $1.59M-5.7% | $1.63M-4.9% | $1.65M-1.8% | $1.67M-0.6% | $1.69M-6.5% | ||
| $18.1M-14.0% | $18.48M-13.6% | $19.82M-7.3% | $20.21M-10.9% | $21.04M-10.8% | ||
| —— | —— | —— | -$19.13M-3,713% | -$9M-576% | ||
| -$1.31M-278% | $326K-56.6% | $759K— | $1K— | $734K— | ||
| —— | —— | $8.28M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$502K-107% | -$503K-106% | ||
| $14K— | $95K— | —— | —— | —— | ||
| $4.11M-4.1% | $4.02M-9.0% | $3.96M-17.3% | $4.09M-10.5% | $4.28M+1.4% | ||
| -$7.65M-3,125% | -$7.12M-1,177% | -$386K+93.4% | -$204K+95.9% | $253K— | ||
| —— | —— | —— | $245.02M+2,892% | $32.53M+294% | ||
| $289.66M+150% | $248.22M+76.4% | $221.01M— | $141.15M— | $115.81M— | ||
| $206.38M+60.7% | $142.98M+2.3% | $117.5M— | $120.5M— | $128.39M— | ||
| -$83.91M— | -$105.87M— | -$90.19M— | -$7.34M— | —— | ||
| —— | —— | —— | —— | —— | ||
| $8.98M+297% | $4.03M+51.7% | $2.58M-2.5% | $2.3M-16.7% | $2.26M-21.6% | ||
| -$7.97M-388% | -$3.25M-30.1% | -$2.12M+93.5% | -$2.09M+96.7% | -$1.64M+98.9% | ||
| —— | —— | —— | —— | —— | ||
| $27.53M+22,465% | $27.88M+25,482% | $21.77M+98,859% | $9M+40,818% | $122K+1,425% | ||
| $3.11M+25.1% | $2.83M+12.8% | $2.3M+7.9% | $2.33M+33.8% | $2.48M+57.8% | ||
| -$7.65M-3,125% | -$7.12M-1,177% | -$386K+93.4% | -$204K+95.9% | $253K— | ||
| —— | —— | —— | -$502K-107% | -$503K-106% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$2.09M-472% | ||
| $1.84M— | $3.36M— | -$927K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $232K-66.3% | $27.1M+2,705% | $1.42M+771% | $7.62M+609% | $689K-71.2% | ||
| —— | —— | —— | $204K-46.0% | $927K+342% | ||
| —— | $2.46M-3.3% | $2.52M-0.2% | $2.58M+3.0% | $2.56M+5.4% | ||
| $4.11M-4.1% | $4.02M-9.0% | $3.96M-17.3% | $4.09M-10.5% | $4.28M+1.4% | ||
| $1.59M-5.7% | $1.63M-4.9% | $1.65M-1.8% | $1.67M-0.6% | $1.69M-6.5% | ||
| $14K— | $95K— | —— | —— | —— | ||
| $10.67M+13.4% | $10.48M+5.8% | $7.6M+16.2% | $8.8M+106% | $9.41M+261% | ||
| $206.38M+60.7% | $142.98M+2.3% | $117.5M— | $120.5M— | $128.39M— | ||
| -$7.65M-3,125% | -$7.12M-1,177% | -$386K+93.4% | -$204K+95.9% | $253K— | ||
| —— | —— | —— | —— | —— | ||
| $27.53M+22,465% | $27.88M+25,482% | $21.77M+98,859% | $9M+40,818% | $122K+1,425% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Theravance Biopharma generate?
- Theravance Biopharma (TBPH) generated $323.5M in operating cash flow over the trailing twelve months.
- Where does Theravance Biopharma's cash flow data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
